Recombinant human EpCAM /CD326 Protein, Fc Tag, 100µg

Background
EpCAM is also known as CO171A,; EGP; EGP40; GA7332; KSA; M4S; MIC18; MK1; TROP1; hEGP2, and is a pan-epithelial differentiation antigen that is expressed on almost all carcinomas as 17-1A(mAb) antigen. Its constitutional function is being elucidated. It is intricately linked with the Cadherin-Catenin pathway and hence the fundamental WNT pathway responsible for intracellular signaling and polarity.[1] The epithelial cell adhesion molecule (Ep-CAM) is known to express in most epithelial malignancies and was reported as a tumor marker or a candidate of molecular targeting therapy.[2] Ep-CAM cross signaling with N-cadherin involves Pi3K, resulting in the abrogation of the cadherin adhesion complexes in epithelial cells was reported.[3] And Epithelial cell adhesion molecule (Ep-CAM) recently received increased attention as a prognostic factor in breast cancer.[4]

Source
Recombinant Human EpCAM /CD326 Protein, With C-Fc Tag (rhEpCAM-Fc), Gln24-Lys265 (Accession # AAH14785.1) was expressed in human 293 cells (HEK293).

Molecular Characterization
rhEpCAM-Fc, fused with Fc region of human IgG1 at the C-terminus and has a calculated MW of 54 kDa after removal of signal peptide. The predicted N-terminus is Gln 24. In DTT-reduced SDS-PAGE, rhEpCAM-Fc protein migrates as 60-65 kDa poly peptide due to glycosylation.

Endotoxin
Less than 1.0 EU per µg of the protein by LAL method.

Purity
>98% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

References

(1) Linnenbach, et al. (Apr 1993). Mol Cell Biol 13 (3): 1507–15
(2) Akita H, et al. (Mar.2011).Oncogene
(3) Winter MJ, et al. (Aug.2007).Mol Cell Biochem. 302(1-2):19-26
(4) Schmidt M, et al.(Feb. 2011). Breast Cancer Res Treat. 125(3):637-46